MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjcard.2024.06.009

Медицинская библиотека · The American journal of cardiology · 2024

TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement.

Grayburn Paul A, Kodali Susheel K, Hahn Rebecca T, Lurz Philipp, Thourani Vinod H, Kozorovitsky Efraim Roe, Gilmore Suzanne Y, Vinekar Chandan, Zhang Bonnie, Boulware Kristin, Krzmarzick Ann M, Nguyen Don, Vu Minh T, Feldman Ted, Mack Michael J, Leon Martin B

Протокол клинического исследованияСтатьяПеревод пока не подготовлен

Аннотация

Severe tricuspid regurgitation remains largely undertreated given limited treatment options. Transcatheter tricuspid valve interventions have emerged as a promising therapy for these patients, and the TRISCEND II pivotal trial is the first randomized controlled trial to evaluate transcatheter tricuspid valve replacement (TTVR). The TRISCEND II pivotal trial studies the transcatheter EVOQUE (Edwards Lifesciences, Irvine, California) tricuspid valve replacement system using a United States Food and Drug Administration Breakthrough Device Designation-a program intended to provide timely access to medical devices by speeding up development, assessment, and review. The TRISCEND II trial is a prospective, multicenter trial that randomizes patients with symptomatic severe tricuspid regurgitation to treatment with either TTVR in conjunction with optimal medical therapy or optimal medical therapy alone. The trial's novel 2-phase design evaluates 30-day safety and 6-month effectiveness end points for the first 150 patients in the initial phase and a 1-year safety and effectiveness end point for the full cohort of 400 patients in the second phase. The TRISCEND II trial's 2-phase trial design provided an opportunity for early review and led to the first commercial approval of a TTVR system. In conclusion, the design of the TRISCEND II trial will likely inform future transcatheter tricuspid device trials.

Для цитирования: Grayburn Paul A, Kodali Susheel K, Hahn Rebecca T, Lurz Philipp, Thourani Vinod H, Kozorovitsky Efraim Roe, Gilmore Suzanne Y, Vinekar Chandan, Zhang Bonnie, Boulware Kristin, Krzmarzick Ann M, Nguyen Don, Vu Minh T, Feldman Ted, Mack Michael J, Leon Martin B. TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement.. The American journal of cardiology. 2024. DOI: 10.1016/j.amjcard.2024.06.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.